France’s Sanofi-Pasteur, the world’s largest vaccine maker, said Friday it hopes to introduce a dengue vaccine in 2014 to some high-risk nations, AlertNet reports. The vaccine is in the last stage of clinical testing in Australia, and the company said it hopes to produce 100 million doses of the vaccine annually, according to the news agency.

More than half of the world’s population is at risk of the mosquito-borne disease, and there currently is no cure or vaccine. An estimated 220 million infections occur worldwide each year, and about two million people, mostly children in Asia and Latin America, develop a serious form of the disease called dengue hemorrhagic fever, AlertNet notes (Girardon, 5/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.